Yiming Angke Biomedical Technology (Shanghai) Co., Ltd. is a scientific research-oriented biotechnology company dedicated to developing innovative cancer immunotherapy. The company was incorporated in 2015 and is one of the few biotechnology companies in the world that can systematically utilize innate immunity and adaptive immune systems. By strictly adhering to the “Drug-by-Design” concept and using our R&D platform, we have designed a rich pipeline portfolio, including more than ten innovative drug candidates and eight ongoing clinical projects. Our pipeline is based on the deep and broad asset portfolio of innate immunity, which reflects our deep understanding of cutting-edge tumor biology and immunology, as well as our expertise in turning scientific research into drug candidates.
Clinical Trials
40
13 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
2015
Active, not recruiting
1
2.5%
Not yet recruiting
12
30.0%
Recruiting
24
60.0%
Suspended
2
5.0%
Terminated
1
2.5%
No approval data available
No news articles found
